jordan pulse -

Amman Ahliyya University, through its Faculty of Pharmacy, has registered a new pharmaceutical patent with the Ministry of Industry and Trade and filed it with the World Intellectual Property Organization (WIPO), in collaboration with the Hashemite University and the University of Jordan.

The research team—Dr. Ismail Mahmoud (Hashemite University), Dr. Hamdi Al-Nsourat (Amman Ahliyya University), Dr. Walehan Al-Shaer, Prof. Dr. Fadwa Odeh, and Dr. Shorouq Al-Sawatri (University of Jordan)—filed the patent under the title:
WO2025158476 - A Pharmaceutical Compound, Method of Preparation Thereof, and Its Use for Treating Cancer.

The team developed a new hybrid compound by chemically linking thymoquinone and doxorubicin, aiming to enhance therapeutic effectiveness and reduce the side effects typically associated with doxorubicin, while maintaining its cancer-fighting properties and ensuring safety for healthy cells.

This milestone aligns with Amman Ahliyya University's ongoing efforts to advance applied scientific research in Jordan and foster innovation among local researchers.

Patent link – WO2025158476